Parsons V, Baldwin D, Moniz C, Marsden J, Ball E, Rifkin I
Department of Renal Medicine, King's College, London, UK.
Nephron. 1993;63(4):379-83. doi: 10.1159/000187238.
To avoid the use of aluminium as a phosphate binder, patients on CAPD who were stable were dialysed against a peritoneal dialysis fluid which was magnesium free. A mixture of calcium and magnesium carbonate was used as a phosphate binder over a period in excess of 1 year. Vitamin D analogues were used in the majority. Results show satisfactory control of hyperparathyroidism with mean parathyroid hormone concentration for the group of 121 pg/ml (normal < 100 pg/ml), calcium concentration of 2.41 mmol/l, magnesium 0.97 mmol/l, phosphate 1.36 mmol/l and aluminium 0.35 mmol/l (normal < 0.2 mumol/l). These results were as good as and better in some respects than a minority using calcium carbonate alone or remaining on aluminium hydroxide, the latter remaining on Mg-containing CAPD fluid.
为避免使用铝作为磷结合剂，对病情稳定的持续性非卧床腹膜透析（CAPD）患者使用无镁的腹膜透析液进行透析。在超过1年的时间里，使用钙和碳酸镁的混合物作为磷结合剂。大多数患者使用了维生素D类似物。结果显示甲状旁腺功能亢进得到了满意的控制，该组患者甲状旁腺激素平均浓度为121 pg/ml（正常<100 pg/ml），钙浓度为2.41 mmol/l，镁浓度为0.97 mmol/l，磷浓度为1.36 mmol/l，铝浓度为0.35 mmol/l（正常<0.2 μmol/l）。这些结果在某些方面与少数单独使用碳酸钙或继续使用氢氧化铝的患者一样好甚至更好，后者继续使用含镁的CAPD液。
